By Darshan Kulkarni, PharmD, MS, JD
Advances in medicine are bringing new trial therapies into Phase 1, creating opportunities for compounding pharmacies to support research. However, Federal regulations, including the FD&C Act, impose strict cGMP requirements to ensure subject safety. This guide explains how pharmacies can meet those requirements.
Introduction
CVS, Walgreens and other pharmacy chains just tried to make a go at clinical research. They have not been as successful as hoped. This opens up an opportunity for nimble, profitable pharmacies looking to meet the needs of innovative drug manufacturers.
As medical innovation advances, compounding pharmacies are increasingly presented with unique, lucrative opportunities to manufacture and package formulations for investigational studies. However, stepping into the realm of human clinical trials introduces a rigorous and highly scrutinized regulatory paradigm.
For Phase 1 clinical trials, traditional commercial manufacturing regulations under 21 CFR Part 211 are generally exempt by operation of 21 CFR 210.2(c). However, this exemption does not give manufacturers a free pass. Instead, compounding pharmacies must strictly adhere to the foundational statutory requirements of the Federal Food, Drug, and Cosmetic Act. This critical statutory section mandates that all investigational new drugs conform to current Good Manufacturing Practice, or cGMP, to ensure subject safety, identity, strength, quality, and purity.
At the Kulkarni Law Firm, we focus on bridging the operational gap between specialized pharmacy compounding and the complex expectations of the Food and Drug Administration. We help compounding pharmacies establish compliant frameworks, mitigate operational and liability risks, and successfully prepare investigational products for human trials.
Establishing a Compliant Quality Control Function
Implement an independent QC unit with a written plan outlining its roles and responsibilities. For example, define clear procedures for material review, testing protocols, batch release decision-making, and deviation investigations. Each step should have defined owners to ensure no workflow gaps.
Specifically, pharmacies must draft and operationalize plans at least the following to create a clear delineation of critical workflows:
- Material Examination: Develop strict protocols for examining raw materials, components, containers, closures, and labeling to ensure they meet defined, relevant quality standards before being introduced to production.
- Procedure Review: Draft, review, and formalize written manufacturing procedures, testing methodologies, and definitive product acceptance criteria.
- Batch Release Decisions: Establish independent processes for the cumulative review of completed manufacturing records to officially release or reject each batch of an investigational drug.
- Deviations and Investigations: Design structured workflows to investigate unexpected analytical results, errors that occur during manufacturing, or product complaints, followed by the execution of corrective actions.
For smaller compounding environments, the same personnel may occasionally be forced to perform both manufacturing and QC roles due to organizational size. However, depending on the type of product in question, guardrails need to be established. Our Firm can help arrange for an independent, qualified individual not involved in the manufacturing operation to conduct essential, periodic reviews of manufacturing records and QC activities.
Control of Components, Containers, and Closures
Material traceability is critical in clinical research and especially in Phase 1 studies. The Kulkarni Law Firm assists pharmacies in establishing airtight written procedures for the handling, receipt, segregation, and labeling of components from receipt to final use. A pharmacy may rely on us to create structured logbooks and inventory systems that capture key attributes including receipt dates, shipment quantities, supplier names, material lot numbers, storage conditions, and expiration dates.
Pharmacies may also need to rigorously evaluate Certificates of Analysis and sourcing documentation. Critically, pharmacies should not simply rely on COAs but must appropriately perform confirmatory identity testing on each batch of the Active Pharmaceutical Ingredient or drug substance used in the investigational drug product.
Facility, Equipment, and Environmental Control
Compounding for clinical trials frequently occurs in laboratory settings that may not be exclusively dedicated to a single study product. The FDA expects a comprehensive, systematic evaluation of the manufacturing environment to eliminate or mitigate hazards like cross-contamination. We counsel pharmacies on implementing industry-standard procedural controls, which include:
- Ensuring adequate workspace separation, orderly air quality management such as the strategic integration of laminar flow hoods, and meticulous cleaning regimes to prevent carry-over in multi-product environments.
- Drafting and maintaining thorough equipment logs that document the calibration, maintenance, and cleaning of all equipment.
- Advising on the strategic adoption of closed process systems, disposable equipment, and commercial, prepackaged materials to minimize cleaning burdens and optimize compliance efficiency.
Rigorous Document and Laboratory Controls
The FDA famously says: “If it’s undocumented, it didn’t happen.” This is especially true in clinical trials and in manufacturing. The Kulkarni Law Firm helps design comprehensive manufacturing and analytical recordkeeping systems capable of completely replicating the process. This includes tracking raw manufacturing data, capturing justifications for any procedural updates between subsequent batches, and logging precise explanations if a batch is initiated but not completed.
On the laboratory side, we establish scientifically sound, specific, and reliable testing methods. We align pharmacy practices with FDA sample retention expectations, ensuring that a representative sample of both the API and the finished investigational drug is retained in its clinical container for at least two years following the termination of the trial or the withdrawal of the Investigational New Drug application.
Conclusion: Securing Your Foothold in Clinical Research
Entering the clinical research space is a transformative milestone for a compounding pharmacy, but it rachets up the pressure to meet the needs of patients taking a product that may never have been used in humans. It requires shifting from traditional pharmacy compounding to a rigorous, data-driven manufacturing mindset. Failure can stall vital clinical trials, trigger severe regulatory penalties, and compromise human subject safety.
By aligning your operations with the FDA’s formal roadmap, the Kulkarni Law Firm ensures your pharmacy builds a legally sound, structurally compliant foundation. We review your processes, draft robust quality plans, and insulate your business from liability, allowing you to confidently contract with major clinical sponsors and clinical research organizations.
About the Author
Darshan Kulkarni, PharmD, MS, JD, is the principal attorney of the Kulkarni Law Firm and a dedicated clinical research attorney focusing on multi-agency compliance including FDA regulatory issues, clinical trial legalities, and pharmacy law. As a pharmacist and a lawyer, Dr. Kulkarni possesses a unique, dual perspective on the operational realities of compounding pharmacies and the complex legal mandates governing human clinical trials.
With extensive expertise advising life sciences innovators, contract manufacturers, and institutional sponsors across Investigational New Drug submissions, cGMP guidance implementation, and clinical trial agreements, he helps clients seamlessly navigate the intersection of law and medical research to safely and legally accelerate the development of next-generation therapeutics.
